

PHASE I CLINICAL TRIAL FOR ADVANCED COLON AND PANCREATIC CANCER OPENS IN NEW YORK USING REXIN-G™, THE WORLD'S FIRST TUMOR-TARGETED GENE DELIVERY VECTOR

LOS ANGELES, California, April 4, 2005 - Epeius Biotechnologies Corporation, announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Regin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Regin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Regin-G as an effective treatment for pancreatic cancer. Six out of six initial patients with advanced pancreatic cancer responded favorably to Regin-G, as evidenced by significant shrinkage and/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Regin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.

Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Regin-G™, to seek and destroy metastatic tumors. Following the success of "compassionate use" clinical trials using Regin-G™ for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States. In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that "we are now in excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."

MEDIA CONTACT: Dr. Frederick L. Hall
 President and CEO.
 Phone: 818-771-7344
 FAX: 818-243-7778
 Email: info@epeiusbiotech.com

Website: <http://www.epeiusbiotech.com>;

*Important Note: to reach the person sending the news release, contact:
info@epeiusbiotech.com; (source of news: Epeius Biotechnologies)